A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Subjects From 2 to Less Than 6 Years of Age With Hypertension
Latest Information Update: 11 Dec 2024
Price :
$35 *
At a glance
- Drugs Azilsartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Takeda
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 14 Jun 2023 Planned End Date changed from 22 Jan 2024 to 27 Dec 2023.
- 14 Jun 2023 Planned primary completion date changed from 22 Jan 2024 to 27 Dec 2023.